ASTX727 for myelodysplastic syndromes

A treatment and a condition, followed through the public trial records. Not medical advice. How a status is set

Phase 2 trial. Mid-stage trial in people. As of 19 Nov 2026, from 1 registered trial.

Why this status

  1. 18 Sep 2019: Trial registered, NCT04093570
  2. 30 Sep 2019: Trial started, NCT04093570

The trials

NCT04093570: A Study for Participants Who Participated in Prior Clinical Studies of ASTX727 (Standard Dose)

State
Under way
Phase
Phase 2
People
332 planned
Started
30 Sep 2019
Primary completion
31 Dec 2027
Arms
Main Extension Study: ASTX727, Substudy Arm A: ASTX727 With High-Calorie/High-Fat Breakfast Meal on Day 4, Substudy Arm B: ASTX727 With Low-Calorie/Low-Fat Breakfast Meal on Day 4
Results
None posted
  1. 18 Sep 2019: Trial registered
  2. 30 Sep 2019: Trial started

How the status changed

  1. 19 Nov 2026: First set: Phase 2 trial

About the treatment

Kind of treatment: Drug.

Registries searched: ClinicalTrials.gov, through 17 Nov 2026.